Sinda Bio: The first subject has been dosed in the third key registration clinical study of IBI363/TAK-928.

On August 6, Innovent Biologics announced that the first patient was dosed in its pivotal Phase III clinical study of IBI363, a globally innovative PD-1/IL-2-biased bispecific antibody fusion protein in combination with bevacizumab, compared to investigator's choice of treatment, for the treatment of advanced colorectal cancer with prior standard treatment failure or intolerance.